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Neuropathic pain (NeuP) arises due to injury of the somatosensory nervous system and is both common and
disabling, rendering an urgent need for non-addictive, effective new therapies. Given the high evolutionary
conservation of pain, investigative approaches from Drosophila mutagenesis to human Mendelian genetics
have aided our understanding of the maladaptive plasticity underlying NeuP. Successes include the identi-
fication of ion channel variants causing hyper-excitability and the importance of neuro-immune signaling.
Recent developments encompass improved sensory phenotyping in animal models and patients, brain im-
aging, and electrophysiology-based pain biomarkers, the collection of large well-phenotyped population co-
horts, neurons derived from patient stem cells, and high-precision CRISPR generated genetic editing.Wewill
discuss how to harness these resources to understand the pathophysiological drivers of NeuP, define its
relationship with comorbidities such as anxiety, depression, and sleep disorders, and explore how to apply
these findings to the prediction, diagnosis, and treatment of NeuP in the clinic.Neuropathic pain (NeuP) arises as a consequence of a lesion or
disease of the somatosensory nervous system (Jensen et al.,
2011). It is common, affecting 7%–10% of the general popula-
tion, and its prevalence is projected to increase with the aging
population, diabetes epidemic, and improved cancer survival
(van Hecke et al., 2014). Unfortunately, current drug treatments
for NeuP are inadequate due to both poor efficacy and tolera-
bility (Finnerup et al., 2015). NeuP is also associated with a
high level of disability and a large socio-economic cost: the
global burden of disease survey showed that chronic pain is
the third most important cause of disability-adjusted life-years
worldwide (GBD 2017 Disease and Injury Incidence and Preva-
lence Collaborators, 2018; Rice et al., 2016). The current opioid
epidemic exemplifies the problems associated with long term
treatment of NeuP and the need for alternative non-addictive
therapeutics (Jones et al., 2018). We do not yet have a full
understanding of the drivers of NeuP and the extent to which
they depend on the specific underlying etiology. For example,
are the factors that precipitate NeuP in traumatic nerve injury
and post-herpetic neuralgia the same? Nor do we have a full
explanation as to why, following the same insult, some patients
develop NeuP and others do not. Why for instance do onlyNeuron 104, Nove
This is an open access article und30%–50% of diabetic polyneuropathy patients develop NeuP
(Feldman et al., 2017)? Differences here are likely to depend on
a complex interaction between environmental and genetic
factors that alter both the vulnerability and resilience of the so-
matosensory nervous system. A better understanding of the
genetic architecture of NeuP will therefore provide fundamental
insights into disease pathophysiology, help us understand in-
ter-individual variation in NeuP, and reveal new drug targets.
Despite great efforts, the development of new and effective
treatments for NeuP has proved difficult, with a number of prom-
ising pharmacological targets identified in preclinical studies
failing to achieve clinical efficacy (Percie du Sert and Rice,
2014). The reasons for this are complex, spanning the whole
process of drug development but broadly falling into two cate-
gories: the sensitivity of clinical trials for NeuP therapies due to
the subjectivity of pain reporting, the placebo effect and case
mix (Finnerup et al., 2018) and the ability of animal models to
predict clinical efficacy (Percie du Sert and Rice, 2014).
There have been major advances in gene sequencing
technology and the informatics required to deal with large data
volumes. These are now being applied at a national scale to
health services, for instance, the sequencing of 100,000 wholember 20, 2019 ª 2019 The Authors. Published by Elsevier Inc. 637
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. A Comparison of the Genetic
Investigation and Functional Analysis of
NeuP in Human and Animal Models
The study of NeuP in humans has the obvious
advantage of verbal feedback of the individual’s
subjective experience. The development of rela-
tively non-invasive neurophysiological techniques
has allowed us to further probe for diagnostic and
functional biomarkers in NeuP patients. The house
mouse (Mus musculus) and fruit fly (Drosophila
melanogaster) are genetically modifiable organ-
isms commonly used in studies of nociception and
pain processing. High-throughput genetic and
phenotypic analysis (e.g., nociception) can be
achieved in flies, as well as fish and worms,
whereas complex behavioral traits such as cogni-
tive affect can be assessed in rodents. Apprecia-
tion of plasticity in the fly nervous system has led to
the application of several injury and chemically
induced neuropathy models to this organism
(Khuong et al., 2019). Adult flies are also capable of
learned conditioning to thermal stimuli such that
they subsequently avoid that area of the chamber
even in the absence of heat (Wustmann et al.,
1996). Mutants displaying spontaneous avoidance
behavior that mimics the stimulus-elicited avoid-
ance response in wild-type larvae remain to be
investigated as a possible measure of ongoing
aversive sensation (Heiman et al., 1996). Abbrevi-
ations: CCI, chronic constriction injury; CRISPR/
Cas9, clustered regularly interspaced palindromic
repeats/CRISPR-associated protein-9 nuclease;
DN4, Neuropathic Pain Diagnostic Questionnaire;
EMS, ethyl methanesulfonate; ENU, N-ethyl-N-ni-
trosourea; GWAS, whole-genome association
study; LANNS, Leeds Assessment of Neuropathic
Symptoms and Signs; NPSI, neuropathic pain
symptom inventory; QST, quantitative sensory
testing; SNI, spared nerve injury; SNL, spinal nerve
ligation; TALENs, transcription activator-like
effector nucleases); TMP/UV, trimethylpsoralen/
ultra violet; ZFN, zinc-finger nuclease.
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and Farsides, 2017). The sensory phenotyping of NeuP has
become more precise and can now be combined with large clin-
ical and research cohorts such as the UK-Biobank of 500,000
people (Sudlow et al., 2015). The HEAL initiative in the USA
(https://heal.nih.gov) is also collecting pain outcome measures
and genetic data (Volkow and Koroshetz, 2019) providing oppor-
tunities to create large-scale international consortia (Pascal
et al., 2019). Complementary advances in mouse genetics
have improved the precision of basic research into the discovery
of pain mechanisms. The speed with which we can manipulate
the genome of model organisms such as the fruit fly and mouse,638 Neuron 104, November 20, 2019or even human sensory neurons derived
from stem cells, means we can rapidly
interrogate gene function once genes of
interest are identified. Given the multi-
disciplinary expertise needed to make
full use of these resources, we organized
a joint satellite meeting of the NeuP and
Genetics Special Interest Groups (SIGs)
of the International Association for the
Study of Pain (IASP) at The Jackson Lab-oratory, Bar Harbor, ME (September 10 and 11, 2018), which
inspired many of the ideas presented in this review.
Assessment of NeuP in Patients
The past decade has seen great improvements in the techniques
used to define the sensory profile of NeuP patients (Figure 1).
These include questionnaires to assess pain quality, psycho-
physical tools to assess sensory perception, and alteration of
experimental pain through conditioned pain modulation (CPM).
These questionnaires e.g., NPSI, DN4, painDETECT, and LANSS
(Bennett et al., 2007) incorporate descriptors of sensory symp-
toms to generate a score that helps predict whether the pain is
Figure 2. The Challenges of Conducting Genome-wide Association Studies in NeuP
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mensions of NeuP. Psychophysical tools to test the function of
the somatosensory nervous system have benefited from stan-
dardization of quantitative sensory testing (QST) protocols.
This consistency of reporting enables the generation of large co-
horts of patients from different centers, so enhancing statistical
power (Rolke et al., 2006). Conditioned pain modulation are dy-
namic psychophysical protocols that aim to explore an individ-
ual’s descending pain modulatory system, although the
complexity of the protocols and the variability in the size and
stability of the response remains a challenge (Kennedy et al.,
2016). Deployment of a combination of the above techniques
now enables the stratification of NeuP patients according to
sensory profile, providing a much richer dataset than simply
classifying patients according to etiology (e.g., polyneuropathy
versus post-herpetic neuralgia) and enabling for selection of pa-
tients with specific phenotypes to empower clinical trials (Attal
et al., 2018). There have also been significant advances in the
development of biomarkers which assess neurobiological
processes underlying pain but are not dependent on patient
report, such as neurophysiology (microneurography and evoked
potentials) and neuro-imaging (Tracey et al., 2019). When
different biomarkers are used in combination they can become
objective indicators with adequate specificity and sensitivity to
aid diagnosis and prognosis (Tracey et al., 2019).
Combining such sensory phenotyping and biomarkers with
genetics should provide significant added value in understand-
ing the pathophysiology of NeuP and be of clinical relevance in
terms of diagnosis, prognosis, and treatment choice. Their use
will depend on the cohort being studied. For example, question-
naires can be applied at population level, while QST is only
feasible in patients attending specialized services. However,
standardization of QST protocols has enabled increased cohort
size. These methods have associated gene variants with partic-
ular aspects of the NeuP sensory phenotype, such as paradox-
ical heat sensation (the perception of warmth/heat as the skin is
cooled) (Binder et al., 2011). Brain imaging is now also beingused at the population level; for instance, UK-Biobank plans to
image 100,000 predominantly healthy genome-sequenced
individuals, who will then be followed longitudinally. An initial
analysis has already shown that structural and functional brain
imaging phenotypes are heritable (Elliott et al., 2018), with over
100 genomic regions showing associations with imaging pheno-
types. Although such imaging studies are not undertaken using
an experimental pain model, clinical pain data are being
collected, and they do begin to provide insight into the genetic
basis of brain structure/connectivity. This will help inform on
the brain’s response to disease and explore the hypothesis
that brain circuitry confers resilience or vulnerability to NeuP
(Denk et al., 2014).
The Genetic Epidemiology of NeuP
Genetic epidemiology—the study of the role genetic factors
play in determining health-related states or events in a popula-
tion—is a useful tool to help understand NeuP as it can reveal
genetic variants associated with disease risk (Manolio, 2010).
Genetic epidemiology studies of NeuP have presented a number
of challenges (Figure 2). The first is sample size. In order to detect
genetic associations, particularly those of small effect size, a
study must have sufficient statistical power. In genome-wide
association studies (GWASs) of other conditions, well-powered
cohorts usually exceed ten thousand participants. A recent
example of this is in type 2 diabetes where one study used a
cohort of 74,124 cases and 824,006 controls by combining
genetic data from 32 different studies. This enabled the authors
to identify 243 loci that reached significance (p < 5 3 108) and
accounted for approximately 18% of the variance in risk and
around a half of the estimated overall heritability (Mahajan
et al., 2018). To date, genetic studies of NeuP have typically
analyzed cohorts with fewer than a thousand cases, which
has resulted in only suggestive associations (He´bert et al.,
2017). One reason that genetic studies in NeuP lack sufficient
sample sizes is the costs associated with recruiting, adequately
phenotyping, and genotyping the cohort. A solution to thisNeuron 104, November 20, 2019 639
Figure 3. A Venn Diagram of Genes
Reaching Study Specific or Suggestive
Significance in Human Candidate Gene and
Genome-wide Studies So Far in NeuP and
the Overlap of Biological Pathways
These genes have been summarized in a recent
systematic review of NeuP by Veluchamy et al.
(2018), where the inclusion criteria were any study
analyzing genetic variants in people with NeuP
compared to people without NeuP. The number of
genes and our understanding of their contribution
within these pathways, in the context of NeuP, is
likely to change as more studies are published.
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be combined and meta-analyses can be conducted to boost
sample size and power. Combining such cohorts requires
harmonization between them, which brings us onto the next
challenge. A recent systematic review of genetic studies of
NeuP identified 29 studies, with no two studies using the same
NeuP case definition (Veluchamy et al., 2018). This has made
it difficult to compare the genetic variants and their effect size
estimates across studies, and to combine data to conduct
meta-analyses (Evangelou and Ioannidis, 2013). A robust pheno-
typic definition of NeuP is needed, that all researchers adhere to,
in order to accurately identify cases and controls. A consensus
definition on NeuP has led to international harmony on clinical
NeuP assessment, but these methods are not necessarily
amenable to large populations (Finnerup et al., 2016). In a
research setting, a good NeuP definition and classification into
specific subgroups should be valid (identifying people with and
without NeuP), feasible to use (in terms of the study time, ethics,
and cost), accurate and precise (having high sensitivity and
specificity), and, above all, reproducible. To address this issue,
NeuP SIG have published a set of recommendations for pheno-
typing NeuP (van Hecke et al., 2015). The NeuP Phenotyping by
International Consensus (NeuroPPIC) guidelines provide a set of
entry-level criteria with which to assess participants for NeuP,
including use of a validated NeuP screening tool, anatomical dis-
tribution of pain using a body chart or checklist, and pain history
(including intensity, duration, underlying etiology, and demo-
graphics). However, preliminary analysis of the feasibility of
NeuroPPIC suggests that it may currently be overly stringent,
meaning that larger cohorts than are currently available would
be required to produce a sample size that has adequate statisti-
cal power (unpublished data). This demonstrates the trade-off
between feasibility and validity of phenotyping criteria. A further
complication is the fact that the standard validated NeuP
screening tools do not always agree. A study of the agreement
of the Self-report Leeds Assessment of Neuropathic Symptoms
and Signs (S-LANSS) (Bennett et al., 2005) and Douleur Neuro-
pathique 4 Questions (DN4) (Bouhassira et al., 2005) screening
tools in 45 patients with low back pain or related leg pain re-
vealed only a moderate correlation, albeit statistically significant
(Walsh et al., 2012).
Despite these shortcomings, a number of molecular, candi-
date-gene, and genome-wide studies have been conducted in
humans that are comprehensively summarized in a recent sys-640 Neuron 104, November 20, 2019tematic review (Veluchamy et al., 2018). Investigations eligible
for inclusion were those that examined genetic variants in people
with NeuP compared to people without NeuP. These studies
identified 28 genes that show study-wide association with the
presence of NeuP. Together, these genes provide important
clues as to the biological mechanisms involved in the onset
and persistence of NeuP (Figure 3). The association of variants
in COMT, OPRM1, SCN9A, SLC6A4, and CACNG2 demon-
strates the involvement of neurotransmission. Major histocom-
patibility complex and cytokine genes including HLA-A, HLA-
B, HLA-DQB1, HLA-DRB1, B2M, IL6, IL1R2, IL10, and TNF-a
represent the immune response pathway, and it is interesting
to note that these genes are also associated with underlying
diabetic neuropathy and post-herpetic neuralgia etiologies.
Finally the identification of genes involved in iron metabolism
including ACO1, BMP6, FXN, TF, CP, TFRC, SLC11A2, and
GCH1 illustrates the role of metabolic pathways in neuropathic
sensory dysfunction. Of the genes that were identified in
candidate gene-studies, variants in HLA genes, COMT,
OPRM1, TNF-a, IL6, and GCH1 were found to have an associa-
tion with NeuP in more than one study (Veluchamy et al., 2018).
While other genes including SCN9A have been associated with
pain intensity in neuropathy (Reimann et al., 2010), only the
HLA genes (A, B, and DRB1) have been replicated consistently
as associated with the presence or absence of NeuP in the
same etiology (post herpetic neuralgia) (Sato-Takeda et al.,
2004; Ozawa et al., 1999; Sumiyama et al., 2008). In addition,
polymorphisms in GCH1 that were originally identified as risk
factors in persistent lumbar root pain (Tegeder et al., 2006)
have been associated with NeuP in a further two different
etiologies (HIV-induced sensory neuropathy and persistent post-
surgical pain) suggesting that the recently discovered role of
GCH1 in energy metabolismmay potentially lie at a key intersec-
tion in NeuP development (Cronin et al., 2018). Furthermore,
three GWASs of NeuP have been conducted to date. Two
used a prescription-based phenotype for NeuP (572 and 961
cases) (Meng et al., 2015a, 2015b) and another used knee pain
cohorts screened for NeuP using the painDETECT questionnaire
(331 cases) (Warner et al., 2017). However, none of the loci
identified by these studies (GFRA2, ZSCAN20-TLR12P,
HMGB1P46, or PRKCA) reached genome-wide significance,
again highlighting the importance of sample size and pheno-
type harmonization. Such factors are currently being addressed
by the DOLORisk study (http://dolorisk.eu/) (Pascal et al., 2019),
Neuron
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For this study, a core group of questionnaires has been devel-
oped, based on the NeuroPPIC guidelines. This has been used
to phenotype two Scottish cohorts covering 33,000 individuals.
Furthermore, consenting participants of the UK Biobank cohort
are currently being re-phenotyped for pain using the DN4
questionnaire (originally 500,000). Although the survey is still
being completed, it is expected that responses will be received
from around 175,000 participants. Assuming a NeuP prevalence
of 7% (van Hecke et al., 2014), which is at the lower end of esti-
mations, it is predicted that the number of people with NeuP will
be over 12,000, providing the power to identify novel genetic
variants.
Requiring such a stringent p value threshold (p < 5 3 108)
to deal with multiple testing and protect against type I error (false
association) is in tension with the greater chance of a type II error
(overlooked associated genes). Pathway or gene set enrichment
analysis that combines the association statistics of genes
co-involved in defined signaling pathways can be one way to
deal with this issue. This can be informative on the basis of
aggregate data from multiple SNPs that show suggestive asso-
ciation but which individually do not reach the nominal threshold
of 53 108 (Lo¨tsch et al., 2013; Parisien et al., 2019). Another is
more complex statistical approaches, and with the advent of
machine learning such methods should become more common
(Lo¨tsch and Ultsch, 2018; de Los Campos et al., 2018). Large-
scale genome or exome sequencing will likely become increas-
ingly relevant in these cohorts as the price of these methods
fall. As the sample sizes used in GWASs steadily increase, it is
predicted that single variants will account for between one-
and two-thirds of the heritability of most complex traits (Tam
et al., 2019). While it is unlikely GWAS approaches will be able
to explain all of NeuP heritability, it currently represents the
most powerful approach available to identify genetic risk and
thus targets for new therapies.
Further insights into the genetics of NeuP are being provided
by the recently created Human Pain Genetics Database (HPGdb;
http://humanpaingenetics.org/hpgdb) (Meloto et al., 2018). The
HPGdb provides a central and up-to-date resource listing all
genetic variants associated with pain and related phenotypes,
including NeuP.
How Can Genetic Epidemiology Be Used to Benefit
Patients?
With more complex analysis of multiple genetic variants, atten-
tion inevitably turns to how these variants can be used to benefit
patients and improve quality of life. One route being investigated
is polygenic risk scores (PRSs). Polygenic risk scores quantify an
individual’s overall likelihood of developing a given disorder by
assessing how many known risk alleles that person has and
weighting them according to their estimated effect size from
GWASs. This approach has identified a significant proportion
of people that have more than three times the risk of developing
a disorder, for instance, defining 8% of the population at risk of
coronary artery disease, 20 times more than could be identified
by screening for rare monogenic disorders (Khera et al., 2018).
Although there has been preliminary research into polygenic
risk scores and pain, this has yet to be explored specifically inNeuP due to the lack of highly powered GWAS studies (McIntosh
et al., 2016).
Currently, front-line medications used to treat NeuP, including
gabapentinoids, tricyclic antidepressants, and serotonin-
noradrenaline reuptake inhibitors, achieve only a 30%–50%
reduction in pain severity, in 30% of patients (Finnerup et al.,
2015). In order to improve clinical outcomes for existing medica-
tions and in common with patient association studies, it has
been suggested that patients should be categorized according
to their QST profiles (Forstenpointner et al., 2018). Furthermore,
genetic variants could help explain variation in treatment
response and toxicity of different drugs (pharmacogenetics).
For this, variants need to be sufficiently common in the popula-
tion and confer a clinically meaningful difference in treatment
response. Again detecting these variants relies on large discov-
ery cohorts, with sufficient statistical power. Because of this dif-
ficulty, very few pharmacogenetics studies have been conduct-
ed in NeuP to date (Brasch-Andersen et al., 2011; Chaudhry
et al., 2017). Sensory phenotype stratification, together with
classifying patients depending on genetic risk, has the potential
to lead to personalizedmedicine to determine the best course for
treatment.
Genetic Variants in Ion Channels: From Rare Mendelian
to Common NeuP Disorders
The discovery and investigation of genetic variants in ion chan-
nels is one of the best examples as to how human genetics
can have a profound influence on the pain field. Hyper-excit-
ability of the somatosensory nervous system underpins the
sensory dysfunction of NeuP and is driven by the altered activity
of ion channels. Mutations in ion channels have been found to
underlie rare inherited painful disorders (Fertleman et al., 2006;
Yang et al., 2004), and variants in the same genes have recently
been associated with more common NeuP states (Faber et al.,
2012a; Blesneac et al., 2018).
Most of the genetic variants that alter pain transmission
have been found in three voltage-gated sodium channels:
NaV1.7, NaV1.8, and NaV1.9. All three demonstrate highly en-
riched expression in pain circuits, particularly in nociceptors,
and have important functions in the initiation and proper firing
of action potentials (Dib-Hajj et al., 1998; Akopian et al., 1996;
Bennett et al., 2019). Familial studies of rare variants with high
penetrance that cause NeuP allow us to understand the contri-
butions these channels make to primary afferent excitability.
Gain-of-function mutations in SCN9A (the gene encoding
NaV1.7) lead to inherited erythromelalgia (IEM; pain and ery-
thema of the hands and feet) (Yang et al., 2004) or paroxysmal
extreme pain disorder (PEPD; paroxysmal pain and erythema
of the sacrum and mandible) (Fertleman et al., 2006), while
loss-of-function mutations lead to pain insensitivity (Cox et al.,
2006). The biophysical consequences of these mutations for
channel function are summarized in Figure 4 and have been
described in detail in recent reviews (Bennett et al., 2019; Dib-
Hajj and Waxman, 2019).
IEM and PEPD patients carrying rare variants account for
only a very small proportion of total NeuP sufferers, so how
does their study advance our understanding of NeuP in general?
Beyond providing insight into basic biology, familial studiesNeuron 104, November 20, 2019 641
Figure 4. NaV1.7 Variants Contributing to
NeuP
NaV1.7 is themost studied ion channel with genetic
association to NeuP and represents the canonical
example of how variants can drive disease path-
ogenesis. Schematic illustrates the cardinal bio-
physical changes in NaV1.7 function associated
with rare inherited (IEM and PEPD) and common
NeuP states painful diabetic peripheral neuropathy
(PDPN) and idiopathic small fiber neuropathy.
IEM-associated variants uniquely exhibit hyper-
polarized voltage of activation, whereas PEPD
variants display impaired fast inactivation, which
results in a persistent current in the majority of
cases. Similar to PEPD, PDPN variants also
demonstrate impaired fast inactivation. Small fiber
neuropathy-associated variants show mixed
properties, with impaired slow and fast inactivation
as well as enhanced resurgent currents being
described in different variants. Paroxysms of pain
can be initiated by a range of triggers and are
modulated by genetic and environmental factors,
e.g., genetic modifiers, temperature, and meta-
bolic state of diabetes mellitus patients (Blesneac
et al., 2018; Mis et al., 2019). Convergence of these
factors will determine the resultant degree of
primary afferent excitability, which is important in
the initiation and maintenance of NeuP. In this
way, clinical outcome is dependent on the basic
characteristics of the mutation interacting with
modifying factors, explaining why patients with
identical mutations exhibit diverse clinical pheno-
types and why somemutations only result in a pain
phenotype upon a secondary insult.
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conditions. Potentially pathogenic variants in NaV1.7, NaV1.8,
and NaV1.9 have been found in up to 17% of patients with small
fiber neuropathy (Faber et al., 2012a, 2012b; Huang et al., 2014).
In a recent study of patients with diabetic peripheral neuropathy
(DPN), rare NaV1.7 variants were found in 9% of patients with
painful, but not painless DPN (Blesneac et al., 2018), and in a
separate study a single patient with painful DPN was found to
carry a pathogenic mutation in NaV1.8 (Han et al., 2018). The
biological action of these variants may be different in the two
contexts. In idiopathic small fiber neuropathy (SFN), variants
likely contribute directly to degeneration of intra-epidermal nerve
fibers via the hyperexcitability they confer (Persson et al., 2013),
whereas in DPN the presence or absence of variants appears to
impact the pain experienced in the context of fibers that have
already been injured by diabetes mellitus (Blesneac et al.,
2018); it is also possible that such variants have an additive
effect.
Given the clear role of NaV1.7 in inherited pain states, much
effort has been invested in developing analgesic strategies
targeting the channel. While still ongoing, these studies have
met with mixed success. Small-molecule inhibitors have failed
to deliver efficacy in phase II trials of DPN and post-herpetic
neuralgia (McDonnell et al., 2018; Price et al., 2017). In contrast,
one small molecule, BII074, did reach secondary endpoints and
produced a degree of pain reduction for patients with trigeminal642 Neuron 104, November 20, 2019neuralgia (Zakrzewska et al., 2017). However, the specificity of
this compound for NaV1.7 has been questioned (McDermott
et al., 2019).
Developing a specific and effective NaV1.7 inhibitor is beset by
pharmacological challenges, but, by selecting patient cohorts
based on genetics, success in clinical trials may be accelerated.
In the case of rare and highly penetrant mutations, this approach
has already borne fruit. Studies of carbamazepine (CBZ)-respon-
sive IEM patients described that the drug was able to reverse the
hyperpolarized activation associated with the NaV1.7-V400M
mutant, limiting the hyper-excitability of transfected dorsal root
ganglion (DRG) neurons (Fischer et al., 2009). Using the V400M
variant as a seed, structural modeling and thermodynamic
analysis predicted CBZ sensitivity of a second IEM variant,
S241T. This prediction was subsequently confirmed in vitro,
and the strategy was validated when two patients carrying the
S241T mutations reported a reduction in pain following CBZ
treatment in a small double-blind trial (Geha et al., 2016). These
findings have recently been extended to a NaV1.8 variant (Han
et al., 2018). While distinct highly penetrant mutations may be
rare, rational clustering of variants could provide a means to pre-
dict treatment response on an individual basis and is a realistic
ambition given the increasing ease of genetic testing. In common
NeuP conditions, NaV inhibitors may be more effective in pa-
tients in which gain of NaV channel function contributes to pa-
thology. The anticonvulsant lacosamide is a non-selective NaV
Neuron
Reviewchannel blocker, which in early trials exhibited limited efficacy for
NeuP (Finnerup et al., 2015). However, by recruiting only small fi-
ber neuropathy patients with a NaV1.7 variant, a recent double-
blind, placebo-controlled study demonstrated that lacosamide
treatment resulted in a significant reduction in pain scores and
an increase in patient well being (de Greef et al., 2019). Despite
these promising results, onemust be cautious not to infer clinical
phenotype too strongly from gene variation. Of the 13 patients
with a confirmed pathogenic NaV1.7 variant studied by de Greef
et al., seven patients did not report a reduction in pain following
lacosamide (de Greef et al., 2019). Conversely, several variants
in the painful DPN cohort of Blesneac and colleagues exhibited
large changes in channel biophysics, but this resulted in a pain
phenotype only after a secondary insult, i.e., the metabolic com-
plications of diabetes mellitus (Blesneac et al., 2018). These find-
ings imply that dysfunction of an individual variant cannot alone
predict clinical phenotype, nor will all patients carrying a certain
variant respond to treatment equally. This lack of simple transla-
tion between genotype and phenotype is further supported by
familial studies of rare variants, where pain onset and severity
can vary drastically, even between family members carrying
the same highly penetrant mutation (McDonnell et al., 2016),
implying a significant contribution of other genetic and environ-
mental factors to the disease phenotype (Figure 4). Defining
these interactions is a key challenge andwill undoubtedly require
different strategies and experimental modeling of ion channel
variants and indeed any genetic differences.
Using Human Cellular Models to Study NeuP
Advances have been made in developing new cellular models
capable of investigating the interaction of gene variants with
phenotype, with induced pluripotent stem cell (iPSC) technology
at the forefront of recent work. This approach offers the ability to
investigate the functional consequence of disease-associated
variants in a human neuronal cell model that retains the entire ge-
netic background of the patient. The benefit of iPSC technology
is limited by the availability of differentiation protocols to
generate physiologically accurate somatic cell types, but proto-
cols are available to generate neurons akin to nociceptors
(Chambers et al., 2012). Currently, iPSC-derived nociceptor
neurons are only an approximation of their endogenous counter-
parts and do not replicate the full panoply of sensory neuron sub-
types; however, this is an ever-evolving field. Further protocols
have since been published, including for the trans-differentiation
of fibroblasts directly to nociceptors, which offers a larger reper-
toire of sensory neuron subtypes (Blanchard et al., 2015;
Schrenk-Siemens et al., 2015).
In the first experiment of its kind, IEM was modeled in patient
iPSC-derived nociceptors, which exhibited many features of
hyper-excitability, including reduced threshold for firing and
spontaneous activity (Cao et al., 2016). This study then neatly
translated a novel NaV1.7 blocker, which reduced IEM iPSC-no-
ciceptor excitability in vitro and resulted in a degree of pain
reduction in donor patients. Although the study was small,
there was a correlation between the patient iPSC lines that
responded to the drug in vitro, and the patients who exhibited
drug responsiveness (Cao et al., 2016). While in vitro phe-
notypes for monogenic disorders have been observed (McDer-mott et al., 2019; Cao et al., 2016), it remains unclear whether
this approach will be sensitive enough to investigate variants
with small effect sizes due to the inherent variability between
iPSC lines. A recent study that compared two IEM patient lines,
derived from a mother and son both carrying the NaV1.7 S241T
mutation but who exhibited stark differences in pain severity
(Mis et al., 2019), gives cause for optimism. The authors
demonstrated differential excitability between the two cell lines
consistent with the clinical phenotype and then, by a process
of whole-exome sequencing followed by dynamic clamp
studies, provided evidence of a second variant in the gene
KCNQ2 capable of modifying neuronal excitability. Such studies
suggest that iPSC may enable the separation of polygenic fac-
tors underlying pain pathogenesis.
iPSC are highly amenable to CRISPR genome editing and
correction of predicted pathogenic variants to generate isogenic
controls is a powerful tool to causally link variants with in vitro
phenotypes found in iPSCs (McDermott et al., 2019). This
approach will be vital when investigating variants with smaller
effect sizes, or variants that are highly depended on genetic
background. Beyond studying genetic variants, the use of
iPSC-nociceptors as screening platforms may be a substantial
step forward for drug development in NeuP (Cao et al., 2016;
Weir et al., 2017). Once ion channel targets are identified, drugs
can be screened for their selectivity and ability to modulate
neuronal excitability (Namer et al., 2019).
Cadaveric tissue and the potential to study genetic mutations
directly in adult human DRG neurons represents an alternative
in vitro approach. Such tissue is becoming more widely avail-
able, allowing for studies into cellular physiology and the contri-
bution of key ionic currents to excitability (Zhang et al., 2017).
Recent experiments have been undertaken to profile the
electrophysiological responses of DRG neurons derived from
NeuP patients (Li et al., 2018; North et al., 2019), opening up
exciting avenues for experimentation. It may be unrealistic to
consider obtaining DRG from patients with rare variants, but
studies assessing DRG neurons from patients with NaV-related
small fiber neuropathy/DPN will surely be possible in the future.
It will also be possible to relate these findings in human DRG
neurons to the wealth of sequencing data of mouse counter-
parts, which is beginning to illustrate the heterogeneity of gene
expression and resultant functional properties between different
sub-types of DRG neurons (Zheng et al., 2019). Defining how
these individual neurons respond to nerve injury is an exciting
near-term goal.
The Use of Model Organisms to Study the Genetics
of NeuP
In silico model systems and in vitro cultures of human tissues
provide a novel and important way to assess the molecular
interactions of any given mutation. However, as the pain experi-
ence results from integrated pathways, all the way from sensory
transduction in the periphery to perception in the brain, it is crit-
ical to study this system with each level of processing intact. The
development in the 1980s of transgenic and gene ‘‘knockout’’
mice, in combination with sequencing of the mouse genome in
the early 2000s (Waterston et al., 2002) has led the advance in
research into the molecular genetics of NeuP.Neuron 104, November 20, 2019 643
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The assessment of NeuP in preclinical models is associated with
significant challenges given the need for indirect behavioral
readouts as a surrogate of the pain experience. For practical
reasons, the most commonly assessed behavioral outcomes
are reflex withdrawal thresholds evoked by thermal or mechan-
ical stimuli. Preclinical animal models of traumatic nerve injury,
most often the sciatic nerve or its branches, results in evoked
hypersensitivity of the animal’s hind limb (Wakisaka et al.,
1991; Seltzer et al., 1990; Decosterd and Woolf, 2000; Challa,
2015). This is practically useful as most animals develop
marked levels of pain-like behavior to mechanical or thermal
(hot or cold) stimulation; however, there are some concerns
that such models neither fully mimic traumatic nerve injury, nor
reflect all aspects of nerve injury seen in the clinic. The picture
of preclinical research is being enriched by using animal models
beyond traumatic nerve injury to more faithfully represent
NeuP inducing conditions, such as chemotherapy-induced
polyneuropathies, diabetic neuropathy, multiple sclerosis, or
HIV-associated peripheral neuropathy. Genetics has also been
useful in developing improved models of NeuP. An example is
the use of genetic mouse and rat models of diabetes which
produce a slowly progressive diabetic polyneuropathy rather
than the severe, acute model of streptozotocin-induced neurop-
athy, which is hindered by the direct neurotoxic effects of this
compound (Andersson et al., 2015; Islam, 2013).
In humans, NeuP commonly presents with a complex combi-
nation of different sensory signs and symptoms. Patients with
traumatic peripheral nerve injury for example show thermal
hypersensitivity (increase in cold and/or heat pain sensitivity)
in around 39% of cases, but only 8% of patients with polyneur-
opathy have this symptom (Maier et al., 2010). Mechanical hy-
persensitivity is seen in a third of NeuP patients with mixed
etiologies; specifically blunt pressure is present in 36% of pa-
tients, pinprick sensitivity in 29%, and dynamic mechanical
allodynia in 20% of those studied (Maier et al., 2010). Further-
more, evoked hypersensitivity does not correlate well with re-
ported pain severity (Backonja and Stacey, 2004), except in
certain conditions, such as post-herpetic neuralgia (Rowbotham
and Fields, 1996). Thus, in contrast to mice, hypersensitivity
(sensory gain) is not always present in patients and means we
should not rely on any single outcome measure to inform us of
the full presentation of NeuP in either species.
To address the issue of non-evoked pain in preclinical models,
ethologically relevant behavioral assessment has been sug-
gested as an indicator of ongoing pain-like behavior (Rice
et al., 2008). An example in mice is burrowing behavior, which
is impaired in different models of toxic neuropathies (Griffiths
et al., 2018; Huang et al., 2013), although in nerve-injured ani-
mals this behavior (in addition to animal gait and grooming mea-
sures) does not correlate well with mechanical hypersensitivity
(Andrews et al., 2012; Mogil et al., 2010). Conditioned place-
preference/avoidance provides an external measure of internal
rewarding/aversive perception (Cunningham et al., 2006) and
may help to separate the sensory and affective components of
the pain experience. Neuropathic animals, but not controls, pre-
fer a chamber paired with administration of an analgesic drug,
suggesting the relief of an ongoing aversive state (Tappe-Theo-644 Neuron 104, November 20, 2019dor et al., 2019; King et al., 2009). In vivo calcium imaging in
awake, behaving animals was recently used to show activity in
an amygdala brain circuit driven by innocuous stimuli in neuro-
pathic animals; when this circuit was silenced, mice failed to
develop conditioned place-avoidance but still displayed hyper-
sensitive responses to evoked stimuli (Corder et al., 2019). Other
cognitive behavioral assays such as thigmotaxis in an open
arena, elevated plus-maze, and light-dark box preference are
useful in animal studies of comorbidities of NeuP such as anxiety
(Sieberg et al., 2018).
Defining the Molecular Pathways that Create NeuP
Transcriptional profiling obtained from DRG has revealed the
sheer breadth of gene regulation after neuropathic injury (Ban-
gash et al., 2018; Chen et al., 2017) and demonstrated important
contributions from non-neuronal glial and infiltrating immune
cells (Cobos et al., 2018; Lopes et al., 2017b). A recent compar-
ison of mouse and human DRG transcriptomes revealed highly
conserved enrichment of transcription factors and axonal
trafficking of mRNA providing strong external validity in the use
of mice for drug-protein interactions (Ray et al., 2018).
Conversely, regional differences in sensory neuron gene expres-
sion, such as between spinal and trigeminal sensory ganglion,
could also be exploited for targeted drug discovery (Lopes
et al., 2017a). Beyond mRNA, the extensive non-coding tran-
scriptome may add a further layer of complexity to pain regula-
tion (Baskozos et al., 2019; Zhao et al., 2013).
Sensory ganglia gene expression can also provide insight into
analgesic mechanisms and potential novel analgesic therapies
(Upadhyay et al., 2019). For example, variable DRG carbonic
anhydrase-8 (CA8) expression appears to regulate nociception
inmice through inhibiting intracellular signaling and nerve growth
factor (NGF) responses (Levitt et al., 2017; Zhuang et al., 2018).
Accordingly, DRG transduction of CA8 by viral gene transfer,
associated with selective CA8 expression in small and medium
sensory neurons, produced profound analgesia in mouse
models of NeuP. Targeting sensory ganglia using gene transfer
(CA8 or otherwise) may therefore represent a future therapeutic
approach.
As genetic markers for subpopulations of peripheral sensory
neurons and spinal cord dorsal horn neurons become better
defined (Usoskin et al., 2015; Li et al., 2016; Chiu et al., 2014;
H€aring et al., 2018; Chamessian et al., 2018), it allows for the
ever more refined targeting of specific cells involved to pain
transduction. Single-cell gene profiling has been applied to tis-
sues from neuropathy models to reveal the heterogeneity of
the injury response in regeneration associated genes and cell
death pathways among sensory neuron subsets (Hu et al.,
2016), and expression profiling by ribosome affinity purification
has revealed novel signaling pathways during chemotherapy-
induced peripheral neuropathy in genetically defined sensory
neurons (Megat et al., 2019). Reporter mice conditionally ex-
pressing recombinases such as Cre, Flp, Dre, and more recently
VIKA (Karimova et al., 2018) can then be used to achieve highly
defined expression of chemogenetic and optogenetic tools
(Atasoy and Sternson, 2018; Mickle and Gereau, 2018). Used
in combination with sophisticated electrophysiological prepara-
tions (Hachisuka et al., 2016), the identification of unique cell
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facets of themechanisms of spinal gain-of-function phenomena,
including ‘‘wind-up’’ of nociceptive inputs (Hachisuka et al.,
2018) and the gate-control of innocuous mechanical stimuli
evoking pain (Zhang et al., 2018).
Genetic Homogeneity of Animal Models: A Help or a
Hindrance?
The display of pain behaviors in response to any given NeuP
model are generally consistent between mice of the same strain
but can differ markedly between strains (Mogil et al., 1999). The
use of genetically homogeneous inbred mice for the majority of
pain research has been based on the assumption that a defined
genetic background will be a less variable and more reliable
model than genetically heterogeneous outbred mice (Festing,
1999). Until recently, however, little empirical evidence existed
to back up this assumption (Festing, 2014). A recent compre-
hensive literature review revealed no difference in experimental
outcomes between inbred and outbred lines. Given the same
sample size, outbredmice are phenotypically as stable as inbred
strains (Tuttle et al., 2018). Thus, genetically diverse outbred
models should help avoid strain-specific responses and comple-
ment the study of heritable diseases across a diverse population.
In addition, inbred strains, such as C57BL/6, are commonly
used to provide a homogeneous genetic background with which
to test the effects of a particular gene variant on a given
phenotype (Yoshiki and Moriwaki, 2006). However, the choice
of genetic background can have a dramatic effect on the allele
phenotype, often attributed to background-specific modifier
genes or epigenetic modifications (Sittig et al., 2016). One way
to control for this issue is to repeat the study in at least two
different backgrounds (Linder, 2006). When genetic mutations
are not stable enough to give closely matching phenotypes
across strains of mice, it becomes difficult to predict their
penetrance between species or in a population of patients. In
commonwith GWAS studies, more complex algorithms to define
genetic interactions and their relative importance to phenotype
will undoubtedly improve our understanding of polygenic factors
in animal models (de Los Campos et al., 2018; Capriotti
et al., 2019).
Genetic variation also exists betweenmouse strains in axonal
regeneration (Omura et al., 2015; Tedeschi et al., 2017). The
majority of preclinical nerve injury models are designed to
restrict axonal regrowth by transection or ligation of part of a
peripheral nerve, leading to a permanent, partial denervation
(Shields et al., 2003; Masuda et al., 2017). Recent evidence
also points to a failure of damaged axons to successfully
degenerate and re-innervate as a driver of persistent pain (Xie
et al., 2017; Davies et al., 2019). Strain differences in the
intrinsic neuronal and immune response to injury may also
impact upon the development and/or resolution of the chronic
pain state. Potential biases in strain-specific behavior may be
overcome by use of multiple inbred strains in a single factorial
design that allows a well-powered exploration of genetic het-
erogeneity without substantially increasing sample size (Festing
et al., 2016). Alternatively, a sample of mice from a heteroge-
neous population such as the Diversity Outbred population
may avoid the idiosyncrasies of inbred strains (Tuttle et al.,2018). The precision and allelic diversity of the outbred popula-
tion greatly exceeds conventional inbred mouse strain crosses.
At larger sample sizes, such populations can be used directly
for precise genetic mapping of the variability in response (Recla
et al., 2019).
The discovery of sex-specific effects controlling mouse NeuP
development (Sorge et al., 2015; Taves et al., 2016) has high-
lighted the imbalance between sexes in preclinical animal
models (Clayton and Collins, 2014). Sex-specific immune func-
tion has been linked to variations in pain sensitivity due to hor-
monal changes associated with the menstrual cycle and preg-
nancy (Rosen et al., 2017), or opioid analgesic efficacy (Rosen
et al., 2019), and lend a mechanistic explanation to what has
been suspected clinically for years (Bartley and Fillingim,
2013). Sex differences in the response to a neuropathic injury
may be additionally encoded in the immune system (Lopes
et al., 2017b). This raises interesting questions concerning
expression profiling in chronic pain studies, since changes in
gene expression could represent bona fide transcriptional re-
sponses of pain circuitry, or indicate immune cell recruitment
after injury (Cobos et al., 2018; Lopes et al., 2017b; Davies
et al., 2019). There are also key strain-related differences in
immune function that relate to known NeuP pathways. C57BL/
6 mice showed the highest vulnerability to mechanical hyper-
sensitivity after partial nerve ligation (Isami et al., 2018); in
contrast, mice of the C3H/He strain were more resistant, which
correlated with more anti-inflammatory macrophages (M2) in
the DRG (Isami et al., 2018). The bias of the C57BL/6 strain to
Th1-type inflammatory responses (Watanabe et al., 2004) could
therefore have significant bearing on neuropathies with a strong
immune component.
Reaching across the Evolutionary Divide
When considering an animal model, it is tempting to opt for
fidelity, i.e., the overall likeness of a model to the human
disease. Toward this end, attempts have been made to
improve the relevance of preclinical models of chemo-
therapy-induced NeuP by climbing the evolutionary ladder
from rodents to non-human primates (Hama et al., 2018). In
comparison to rats, for example, macaques reportedly show
a pharmacological response closer to that of patients
following oxaliplatin treatment (Shidahara et al., 2016), with
brain imaging revealing de novo activity in the somatosensory
and insular cortices in response to cold stimulation only in
treated animals (Nagasaka et al., 2017), similar to noxious
thermal stimulation in patients undergoing oxaliplatin treat-
ment (Boland et al., 2014).
It is the principle of discrimination—i.e., the replication of a
specific phenotype in disease modeling (Russell et al., 1959)—
that guides the replacement of higher-order species, such as
monkeys and rodents, with lower-order species including inver-
tebrates (Tannenbaum and Bennett, 2015). Full genome
sequence assembly of Drosophila melanogaster (fruit fly), Cae-
norhabditis elegans (nematode worm), and Danio rerio (zebra-
fish) have allowed these organisms to play an important role in
investigating conserved human disease genes and assisting
drug development, despite fundamental differences in
morphology and organ systems (Strynatka et al., 2018). OneNeuron 104, November 20, 2019 645
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defined, do not vary; there may be duplication and other forms
of molecular evolution, but important pathways and the genes
within them are by and large well conserved once their roles
are established (Lander, 2011). It is also useful to consider the
reasons for the first action potential in the sensory pathway: to
identify and seek out the ‘‘good’’ (i.e., food and a healthy environ-
ment) or conversely to determine and avoid the ‘‘bad’’ (i.e., pre-
dation and toxic environments), the latter resulting in the creation
of nociception and pain. Therefore, biology has processed
noxious stimuli from the very earliest electrically excitable im-
pulses (Smith and Lewin, 2009; Sneddon, 2018), meaning that
both the pain phenotype and the genes that create it appear to
be extremely well conserved across the animal phyla. Although
we are a long way from attributing a perceptive quality such as
‘‘pain’’ to lower organisms, the use of forward genetics has led
to the discovery of gene families that control nociception and
more recent data hinting at the potential evolutionary conserva-
tion of neuropathic mechanisms (Khuong et al., 2019).
Fruit Fly
When it comes to rapid turnaround forward genetics, few organ-
isms have made more contributions to genetic screening than
the fruit fly, Drosophila melanogaster. The archetypal nociceptor
family transient receptor potential (TRP) channels were first
identified phenotypically in flies in the 1960s for their role in sen-
sory perception of light (Cosens andManning, 1969), and the ge-
netic tools available in fly genetics allowed cloning of the first
TRP channel in the 1980s (Montell and Rubin, 1989). The first
application of fruit fly genetics to nociception was in a study by
Tracey et al. (2003), who described a heat assay in fly larvae,
where they exhibit a rapid rolling escape responsewhen touched
with a probe heated to 46C.
Beyond acute nociception, the fly somatosensory system
displays properties of sensitization. Initial assays focused on
sensitization evoked by inflammation (Babcock et al., 2009;
Babcock et al., 2011); however, models of nerve injury are
now being developed (Khuong et al., 2019). Chemotherapeutic
agents can sensitize larvae to mechanical and heat stimuli
(Boiko et al., 2017; Brazill et al., 2018; Hamoudi et al., 2018).
Drosophila larvae also exhibit thermal hypersensitivity following
high-sugar diet or through genetic ablation of insulin signaling,
and this may help in the understanding of diabetic neuropathy
(Im et al., 2018).
While informative with respect to rapid sensitization, fly larval
paradigms are transient by nature and cannot be used to inves-
tigate chronic sensitization. Instead, adult flies have been used
for this purpose. After removal of a leg, adult fruit flies display
enhanced thermal nociception escape responses and exhibit a
heightened state of vigilance (Khuong et al., 2019). This disease
state caused by nerve injury develops after a loss of GABAergic
inhibition in the ventral nerve cord (Khuong et al., 2019), analo-
gous to the vertebrate spinal cord. This mechanism appears to
be the fly equivalent of spinal disinhibition that occurs in mice
after nerve peripheral nerve injury (Mapplebeck et al., 2019).
These findings establish that flies enter a NeuP-like state after
injury that involves permanent central disinhibition, suggestive
of chronic NeuP. A brief summary of fly paradigms is shown in
Figure 1.646 Neuron 104, November 20, 2019Worms and Fish
Modeling of individual characteristics and complications of pe-
ripheral neuropathies in a reductionist approach may help to
define the core machinery involved in NeuP. Nematodes and
zebrafish possess the neural circuitry capable of nociception,
behavioral avoidance, and signal modulation (Chatigny et al.,
2018) making them powerful models for high-throughput and
genetic control for novel analgesic drug discovery (Ellis et al.,
2018). Glucose-induced neurotoxicity in zebrafish was used to
demonstrate the beneficial effect of matrix metalloproteinase
(MMP) inhibition, which paralleled findings in mice (Waldron
et al., 2018), suggesting the conservation of this mechanism of
metabolic neuropathy. Overexpression of gain-of-function
mutations of NaV1.7 in zebrafish sensory neurons led to
decreased small fiber density and increased sensitivity to tem-
perature changes (Eijkenboom et al., 2019), recapitulating the
hallmarks of small fiber neuropathy in patients (Hoeijmakers
et al., 2012).
Reverse genetics in the nematode is enhancing our under-
standing of hereditary peripheral neuropathies. Deposits of
misfolded transthyretin (TTR) protein around sensory and auto-
nomic nerves, characterize familial amyloid polyneuropathy
with NeuP being an early symptom (Sekijima et al., 2018). Intro-
duction of a patient TTR variant to the nematode led to a loss of
noxious heat responses, likely due to the proteotoxicity of TTR
oligomers (Madhivanan et al., 2018). Mutations in serine palmi-
toyltransferase (SPT) cause hereditary sensory and autonomic
neuropathy type 1 in patients, via accumulation of neurotoxic
deoxy-sphingolipids (Garofalo et al., 2011). Insertion of the
equivalent SPT mutation into the nematode led to defects in
neuronal polarization and vesicular trafficking (Cui et al., 2019).
Comorbidities of NeuP
Beyond the seriously debilitating effects of chronic pain, the
presence of multiple comorbidities, including anxiety, depres-
sion, and sleep disorders further complicate patient difficulties
(Davis et al., 2011; Knaster et al., 2012; Radat et al., 2013). For
NeuP, most work has been performed on depression (Humo
et al., 2019; Doan et al., 2015; Barthas et al., 2015). Within the
general population there is an incidence of depression
throughout life of about 16% (Bromet et al., 2011), which com-
pares to a rate of 50% (Bair et al., 2003) in NeuP patients, sug-
gesting strong neurochemical commonalities. Recent data
suggest that chronic pain and depression may share common
genetic and cellular causes, including neuro-inflammation
within the CNS (Lurie, 2018), dysregulation of neurotrophic fac-
tors and neuropeptides (Doan et al., 2015; Humo et al., 2019),
as well as excessive glutamatergic, reduced GABAergic, and
impaired endocannabinoid signaling (Humo et al., 2019). Micro-
glia and astrocytes are resident non-neuronal cells of the brain
and spinal cord that are important endogenous mediators of
neuro-inflammation. Activation of microglia in the amygdala
(Burke et al., 2013) and of astrocytes in the amygdala and peri-
aqueductal gray (PAG) (Norman et al., 2010; Burke et al., 2013)
is seen in neuropathic animals with comorbid symptoms of
depression.
Anxiety in response to acute pain is responsible for hyper-
vigilance as well as other components of the fight or flight
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these responses become chronic and can be detrimental to
overall health, with widespread immune and neural dysfunction
contributing to a vicious cycle of ongoing anxiety and musculo-
skeletal pain (Asmundson and Katz, 2009). It has been shown
that anxiety levels in diabetic neuropathy patients with NeuP
are significantly higher than in subjects without pain (Sieberg
et al., 2018), and that NeuP presents with maximal levels of anx-
iety (Attal et al., 2011).
Research in animals suggests that anxiety is driven by
ongoing painful input over the medium- to long-term rather
than prior anxiety being a driver toward neuropathic hypersen-
sitivity (Sieberg et al., 2018). However, anxiety can modulate
pain in the short term; for example, stress-induced analgesia,
which is an in-built mammalian pain suppression response
that occurs during or immediately following exposure to a
stressful or frightening stimulus (Butler and Finn, 2009). There-
fore, measurements of anxiety levels should not be taken as a
proxy for pain, unless the condition initiating the pain is
adequately defined, again demonstrating the need for careful
phenotyping.
Sleep disturbance is common in NeuP with estimates in
chronic pain patients ranging between 50% and 80% (Cheatle
et al., 2016). Interestingly, the link between sleep and pain is
bi-directional, with lack of sleep amplifying pain perception
(Cheatle et al., 2016; Alexandre et al., 2017). It will therefore be
of interest to understand whether therapies focused on
improving sleep hygiene will also improve NeuP symptoms.
Sleep as a comorbidity may also be considered in relation to
analgesic treatment choice for NeuP. Gabapentin/Pregabalin
have been shown to improve sleep latency and depth in diabetic
neuropathy (Argoff, 2007; Sabatowski et al., 2004), while
conversely Duloxetine can enhance sleep fragmentation (Boyle
et al., 2012).
Despite the clear associations and high prevalence of these
conditions as comorbidities of NeuP, there have so far been
no studies demonstrating shared genetic architecture be-
tween NeuP and depression, anxiety, or sleep disorders. How-
ever, insights can be gained from the few studies that have
been conducted in chronic pain in general. A twins study, for
example, found a genetic correlation of 0.56 between pain
and depression and of 0.69 between pain and sleep disorders
(Gasperi et al., 2017). Similarly, a family-based study found a
strong genetic correlation between chronic pain and depres-
sion (r = 0.51) (McIntosh et al., 2016). Polygenic risk scores
for depression were associated with chronic pain in the
same cohort and in independent samples, but not vice versa
(McIntosh et al., 2016). GWAS studies relating to depression,
anxiety, and sleep disorders have provided some insight into
the potential pleiotropic effect of the genes that have been
found to be associated with NeuP in patients (Veluchamy
et al., 2018) (Figure 3). For example, HLA-B is associated
with feeling miserable and nervous (Nagel et al., 2018b),
HLA-DQB1 is associated with narcolepsy (Han et al., 2013)
and feeling nervous or worried (Nagel et al., 2018b), and
PKRCA is associated with neuroticism (Nagel et al., 2018a).
Further work is required to uncover the genetic overlap be-
tween these comorbidities and NeuP.Conclusions
NeuP is diverse in its clinical phenotype, molecular mechanisms,
and the types of injury that precipitate it. This diversity, in com-
mon with most chronic disease, is due to a mixture of environ-
mental and genetic influences. In order to better treat this dispa-
rate set of pathologies, we urgently need to develop better
means to stratify NeuP into accurately quantified and mechanis-
tically relevant sub-groups (for instance, in terms of distinct sen-
sory profiles) both in humans and in experimental animals. Only
when we can accurately stratify NeuP will we be able to use
whole-genome screens to define individual and shared molecu-
lar mechanisms within these populations. Such stratification will
enable construction of novel therapies and better targeting of
existing therapies for each chronic pain phenotype in turn. In
some cases, such treatments may encompass many neuro-
pathic etiologies; for instance, selectively reducing sodium
current in peripheral nociceptors holds much promise for periph-
eral NeuP disorders. Clearly, the environment plays an important
role in amplifying or diminishing these signaling cascades, and
understanding these factors will be crucial not only for diagnosis
but also for treatment. We have already made huge advances
toward this goal: cross-comparing species has aided the defini-
tion of apex signaling cascades, and the use of model organisms
(chiefly rodents) has been invaluable in the development of our
understanding of pain processing from molecules to neural
circuits and how this might be modulated with drugs or other
therapies. New molecular techniques are currently turbocharg-
ing these advances: next-generation sequencing is now being
applied to large clinical populations, and CRISPR technology
allows rapid functional validation of identified targets in model
organisms. It is our firm belief that we are poised to make a
number of fundamental advances, which should aid the treat-
ment of neuropathic and indeed other types of chronic pain.
To do so, we need to continue to define the genetic architecture
of NeuP, in both patients and model organisms, with the aspira-
tion to move beyond opiates and develop new efficacious and
non-addictive analgesics.ACKNOWLEDGMENTS
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